216 related articles for article (PubMed ID: 18706829)
1. Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study.
van Londen GJ; Levy ME; Perera S; Nelson JB; Greenspan SL
Crit Rev Oncol Hematol; 2008 Nov; 68(2):172-7. PubMed ID: 18706829
[TBL] [Abstract][Full Text] [Related]
2. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
3. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
Elife; 2024 Apr; 13():. PubMed ID: 38656229
[TBL] [Abstract][Full Text] [Related]
4. Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study.
Levy ME; Perera S; van Londen GJ; Nelson JB; Clay CA; Greenspan SL
Urology; 2008 Apr; 71(4):735-9. PubMed ID: 18279933
[TBL] [Abstract][Full Text] [Related]
5. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
Taaffe DR; Buffart LM; Newton RU; Spry N; Denham J; Joseph D; Lamb D; Chambers SK; Galvão DA
BJU Int; 2018 Feb; 121(2):194-202. PubMed ID: 28872752
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of androgen deprivation therapy in prostate cancer patients.
Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
[TBL] [Abstract][Full Text] [Related]
7. Evidence for reduced neuromuscular function in men with a history of androgen deprivation therapy for prostate cancer.
Girard D; Marino FE; Cannon J
Clin Physiol Funct Imaging; 2014 May; 34(3):209-17. PubMed ID: 24119067
[TBL] [Abstract][Full Text] [Related]
8. Persisting adverse body composition changes 2 years after cessation of androgen deprivation therapy for localised prostate cancer.
Cheung AS; Tinson AJ; Milevski SV; Hoermann R; Zajac JD; Grossmann M
Eur J Endocrinol; 2018 Jul; 179(1):21-29. PubMed ID: 29712718
[TBL] [Abstract][Full Text] [Related]
9. The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer.
Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1036-1044. PubMed ID: 31067013
[TBL] [Abstract][Full Text] [Related]
10. Sarcopenia during androgen-deprivation therapy for prostate cancer.
Smith MR; Saad F; Egerdie B; Sieber PR; Tammela TL; Ke C; Leder BZ; Goessl C
J Clin Oncol; 2012 Sep; 30(26):3271-6. PubMed ID: 22649143
[TBL] [Abstract][Full Text] [Related]
11. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer.
Cheung AS; Hoermann R; Dupuis P; Joon DL; Zajac JD; Grossmann M
Eur J Endocrinol; 2016 Sep; 175(3):229-37. PubMed ID: 27340081
[TBL] [Abstract][Full Text] [Related]
12. Does Use of Androgen Deprivation Therapy (ADT) in Men with Prostate Cancer Increase the Risk of Sarcopenia?
Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
Calcif Tissue Int; 2019 Oct; 105(4):403-411. PubMed ID: 31317232
[TBL] [Abstract][Full Text] [Related]
13. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
14. Quality of life in prostate cancer patients taking androgen deprivation therapy.
Dacal K; Sereika SM; Greenspan SL
J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202
[TBL] [Abstract][Full Text] [Related]
15. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
Taaffe DR; Galvão DA; Spry N; Joseph D; Chambers SK; Gardiner RA; Hayne D; Cormie P; Shum DHK; Newton RU
BJU Int; 2019 Feb; 123(2):261-269. PubMed ID: 30239116
[TBL] [Abstract][Full Text] [Related]
16. Age and androgen-deprivation therapy on exercise outcomes in men with prostate cancer.
Alberga AS; Segal RJ; Reid RD; Scott CG; Sigal RJ; Khandwala F; Jaffey J; Wells GA; Kenny GP
Support Care Cancer; 2012 May; 20(5):971-81. PubMed ID: 21538098
[TBL] [Abstract][Full Text] [Related]
17. A randomised controlled trial to evaluate the efficacy of a 6 month dietary and physical activity intervention for prostate cancer patients receiving androgen deprivation therapy.
Haseen F; Murray LJ; O'Neill RF; O'Sullivan JM; Cantwell MM
Trials; 2010 Aug; 11():86. PubMed ID: 20704726
[TBL] [Abstract][Full Text] [Related]
18. Physical function in men with prostate cancer on androgen deprivation therapy.
Clay CA; Perera S; Wagner JM; Miller ME; Nelson JB; Greenspan SL
Phys Ther; 2007 Oct; 87(10):1325-33. PubMed ID: 17684084
[TBL] [Abstract][Full Text] [Related]
19. The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis.
Haseen F; Murray LJ; Cardwell CR; O'Sullivan JM; Cantwell MM
J Cancer Surviv; 2010 Jun; 4(2):128-39. PubMed ID: 20091248
[TBL] [Abstract][Full Text] [Related]
20. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
Harrington JM; Schwenke DC; Epstein DR; Bailey DE
Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
